SOLITON, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01. Regulation FD Disclosure

--------------------------------------------------------------------------------

On January 27, 2020, Soliton, Inc. (the "Company") issued a press release announcing positive data from extended keloid and hypertrophic scar trials. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit
No.     Exhibit

99.1      Press release of Soliton, Inc. dated January 27, 2020


                                   Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SOLITON, INC.


  By: /s/ Lori Bisson
      Lori Bisson
      Executive Vice-President,
      Chief Financial Officer

Dated: January 27, 2020

© Edgar Online, source Glimpses